Anybody who’s used an inhaler to treat asthma or allergies is familiar with the medicinal aftertaste. That taste is more than an annoyance-it’s a sign that a portion of the drug is going to waste in the back of the throat rather than in the lungs where it’s needed. Battelle Pulmonary Therapeutics-a company spun off in April from Battelle Memorial Institute in Columbus, Ohio-is aiming to deliver inhalable drugs more efficiently with new “electrohydrodynamic,” or EHD, aerosol technology.
EHD devices use voltage, rather than pressure, to create a “soft cloud” of aerosolized drug. The patient inhales the cloud, rather than having aerosol shot into the mouth at a velocity that propels drug particles against the throat. The new company believes EHD technology will be valuable against a number of respiratory diseases and infections, including bronchitis and pneumonia. As TR went to press, the startup had signed two licensing agreements-one to commercialize an anti-viral device-and was working on several other deals.
The therapists using AI to make therapy better
Researchers are learning more about how therapy works by examining the language therapists use with clients. It could lead to more people getting better, and staying better.
Can Afghanistan’s underground “sneakernet” survive the Taliban?
A once-thriving network of merchants selling digital content to people without internet connections is struggling under Taliban rule.
The US crackdown on Chinese economic espionage is a mess. We have the data to show it.
The US government’s China Initiative sought to protect national security. In the most comprehensive analysis of cases to date, MIT Technology Review reveals how far it has strayed from its goals.
Where computing might go next
The future of computing depends in part on how we reckon with its past.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.